left-arrow right-arrow pinterest facebook google_plus linkedin

ECOG-ACRIN EA6134

Status:

Recruiting | Phase III

Original Title:

Testing Therapy Sequence for Advanced BRAF Mutation Melanoma

Study Purpose:

The purpose of this study to compare the good and bad effects of the sequence of immunotherapy followed by BRAF inhibitor therapy if and when it gets worse.

Interventions:

  • Group 1: Immunotherapy=Ipilimumab and Nivolumab and at Disease Progression BRAF Inhibitor Therapy=Dabrafenib and Trametinib
  • Group 2: BRAF Inhibitor Therapy=Dabrafenib and Trametinib and at Disease Progression Immunotherapy=Ipilimumab and Nivolumab
  • Quality of Life surveys
  • After completion of the study patients will be followed for 5 years   

Key Participation Requirements:

Gender:

Male or Female

Age:

19 years and older

Diagnosis:

Stage III or IV Melanoma

Eligibility:

Patients qualify if melanoma cannot be removed by surgery.

Patients qualify if finished with chemotherapy, immunotherapy, or other therapy by 4 weeks or longer.

Women must not be pregnant or breast feeding.

Methodist Health System Trial Code:

ECOG-ACRIN EA6134

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!